

Vasomotor Symptoms - Pipeline Insight, 2021

<https://marketpublishers.com/r/VC399F25B11AEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: VC399F25B11AEN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Vasomotor Symptoms - Pipeline Insight, 2021," report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in Vasomotor Symptoms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Vasomotor Symptoms Understanding

Vasomotor Symptoms: Overview

Vasomotor symptoms (VMS), commonly called hot flashes or flushes (HFs) and night sweats, are considered as the cardinal symptoms of menopause. VMS are a form of temperature dysfunction that occurs due to changes in gonadal hormones. Vasomotor symptoms includes hot flashes, night sweats, heart palpitations, and changes in blood pressure. Most women experience hot flashes for 6 months to 2 years, although some women have them for 10 years or longer. Hot flashes occur in approximately 75 to 80 percent of menopausal women in the United States. Hormone therapy, antidepressant drugs and lifestyle modification are ways to manage vasomotor symptoms. Lifestyle modifications, including reducing core body temperature, regular exercise, weight management, smoking cessation, and avoidance of known triggers such as hot drinks

and alcohol, may be recommended to reduce mild vasomotor symptoms.

'Vasomotor Symptoms - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vasomotor Symptoms pipeline landscape is provided which includes the disease overview and Vasomotor Symptoms treatment guidelines. The assessment part of the report embraces, in depth Vasomotor Symptoms commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasomotor Symptoms collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vasomotor Symptoms R&D. The therapies under development are focused on novel approaches to treat/improve Vasomotor Symptoms.

Vasomotor Symptoms Emerging Drugs Chapters

This segment of the Vasomotor Symptoms report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vasomotor Symptoms Emerging Drugs

Donesta: Mithra Pharmaceuticals

Donesta (Estetrol) is an estrogen based drug candidate as a new generation of Hormone Therapy. Mithra Pharmaceuticals is currently evaluating Estetrol (E4) in Phase III clinical studies as an oral therapy for Vasomotor Menopausal Symptoms (VMS) relief.

Q-122: QUE Oncology

Q-122 is an orally available small molecule based CXCR4 receptor antagonists. It is currently being studied in Phase II developmental studies for the treatment of hot flashes in women diagnosed with breast cancer who are receiving hormonal therapy.

Further product details are provided in the report

Vasomotor Symptoms: Therapeutic Assessment

This segment of the report provides insights about the different Vasomotor Symptoms drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Vasomotor Symptoms

There are approx. 9+ key companies which are developing the therapies for Vasomotor Symptoms. The companies which have their Vasomotor Symptoms drug candidates in the most advanced stage, i.e. Phase III include, Mithra Pharmaceuticals.

Phases

DelveInsight's report covers around 9+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Vasomotor Symptoms pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vasomotor Symptoms: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vasomotor Symptoms therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasomotor Symptoms drugs.

Vasomotor Symptoms Report Insights

- Vasomotor Symptoms Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Vasomotor Symptoms Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Vasomotor Symptoms drugs?

How many Vasomotor Symptoms drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vasomotor Symptoms?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vasomotor Symptoms therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Vasomotor Symptoms and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Mithra Pharmaceuticals

Acer Therapeutics

QUE Oncology

Bayer

Endoceutics

Astellas Pharma

Mitsubishi Tanabe Pharma

MenoGenix

Key Products

Donesta

Osanetant

Q-122

Elinzanetant

Acolbifene + prasterone

Fezolinetant

Elismetrep

Filgrastim

Contents

Introduction

Executive Summary

Vasomotor Symptoms: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Vasomotor Symptoms – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Vasomotor Symptoms companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Vasomotor Symptoms Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Donesta: Mithra Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Q-122: QUE Oncology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report
Early Stage Products (Phase I)
 Comparative Analysis
Drug name: Company name
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
 Comparative Analysis
Osanetant: Acer Therapeutics
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report
Inactive Products
 Comparative Analysis
Vasomotor Symptoms Key Companies
Vasomotor Symptoms Key Products
Vasomotor Symptoms- Unmet Needs
Vasomotor Symptoms- Market Drivers and Barriers
Vasomotor Symptoms- Future Perspectives and Conclusion
Vasomotor Symptoms Analyst Views
Vasomotor Symptoms Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Vasomotor Symptoms

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Vasomotor Symptoms
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Vasomotor Symptoms - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/VC399F25B11AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VC399F25B11AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970